NovoCure Earnings Call Highlights Growth, One-Time Hit

NovoCure Ltd. ((NVCR)) has held its Q1 earnings call. Read on for the main highlights of the call.

NovoCure’s latest earnings call struck a cautiously upbeat tone as management highlighted a strong commercial start to 2026 and a maturing clinical pipeline. Double‑digit revenue growth, rapid Optune Pax uptake and improving margins supported an optimistic narrative, even as one‑time stock‑based compensation charges, reimbursement uncertainty and trial strategy questions clouded reported profitability.

Revenue Momentum and Upgraded Outlook

NovoCure reported Q1 2026 net revenue of $174 million, up 12% year over year, citing strength in its core tumor treating fields franchise. Management responded by raising full‑year revenue guidance to $690 million–$710 million, implying 5%–8% growth and signaling confidence that early‑year momentum can be sustained.

Global Active Patient Growth Across Key Regions

The company’s patient base continued to expand, with global active patients up 9% from a year ago. Japan led with 20% growth, while Germany and France grew 12% and 9% respectively, and the global market segment advanced 17% on strong demand in Spain.

Optune Pax: Fast FDA Approval and U.S. Launch Traction

Optune Pax won FDA approval on February 11, 2026, and NovoCure moved quickly to commercialize the therapy. By quarter‑end, 868 healthcare providers were certified, the company had received 169 prescriptions and converted these into 90 patient starts, with 83 patients on therapy and a growing backlog.

Early Reimbursement Wins Support Pax Adoption

A key early validation came from Elevance Health, which became the first major U.S. payer to cover Optune Pax, adding more than 30 million covered lives. Management emphasized that contractual relationships already exist with most U.S. payers, with formal coverage policies now the main hurdle to broader reimbursement.

PANOVA‑4 Delivers Encouraging Pancreatic Cancer Data

NovoCure reported positive topline results from the PANOVA‑4 study in metastatic pancreatic cancer, a notoriously hard‑to‑treat indication. The trial met its primary endpoint with a 74% disease control rate versus a 48% historical control and showed a median therapy duration of 25.6 weeks, supporting feasibility of TTFields in this setting.

Product Enhancements Lift Patient Experience and Persistence

Management highlighted several product upgrades, including an HCP portal, lighter Optune Gio arrays and a new mobile app to streamline use. These changes helped lift 90‑day persistence from below 70% in 2024 to about 73% in 2025, while a new torso array design completed usability testing and should be available for trials by year‑end.

Optune Lua Builds Revenue and Expands Internationally

Optune Lua continued its gradual build, with Q1 2026 net revenue doubling to $3 million from $1.5 million a year earlier. The therapy also secured national reimbursement in Japan in March, and commercial patient treatments have now begun, adding another pillar to NovoCure’s international growth story.

Margin Expansion and Adjusted EBITDA Near Breakeven

Profitability metrics improved beneath the surface, with gross margin rising to 78% from 75% on lower array costs and better supplier pricing. Adjusted EBITDA narrowed sharply to a loss of just $0.3 million from a $5 million loss a year ago, and the company now guides to full‑year adjusted EBITDA between negative $15 million and breakeven.

Pipeline and Strategic Catalysts on the Horizon

Investors are watching several upcoming readouts, led by TRIDENT Phase III data in Q2 testing earlier Optune Gio use with chemoradiation. NovoCure is also advancing large trials such as KEYNOTE D58, expected to fully enroll over 700 patients by year‑end, and is exploring combinations of TTFields with RAS inhibitors after promising preclinical synergy.

Solid Cash Position Underpins Growth Investments

The balance sheet remains a source of comfort, with $432 million in cash and investments as of March 31, 2026. Management argued this provides sufficient runway to support ongoing product launches, reimbursement work and the company’s broad clinical development program.

GAAP Net Loss Widened by One‑Time Compensation Charge

Despite underlying progress, reported GAAP metrics deteriorated as net loss widened to $71 million in Q1 from $34 million a year earlier, or a loss per share of $0.62. Management stressed that a one‑time $43 million share‑based compensation expense tied to Optune Pax approval drove much of the gap versus underlying performance.

G&A Surge Reflects Non‑Recurring Expense

General and administrative costs nearly doubled to $86 million, up 92% year over year, largely due to that same $43 million stock‑based compensation charge. The company noted that the related grant did not vest and no shares were issued, implying the spike should not repeat at similar magnitude.

Profitability Still Negative Despite Adjusted Improvement

Even with better margins, NovoCure remains shy of profitability, with adjusted EBITDA slightly negative and full‑year guidance still allowing for a loss up to $15 million. Management framed this as a deliberate investment phase, but investors will be watching for a clear path to sustained positive earnings.

Limited Near‑Term Revenue From New Indications

While Optune Pax and Optune Lua show promising clinical and early commercial signals, their near‑term financial impact will be modest. Combined 2026 revenue guidance for the two indications is just $15 million–$25 million, underscoring that the bulk of growth this year will still come from established uses.

Reimbursement and Adoption Timelines Remain Uncertain

NovoCure cautioned that it will take multiple quarters to fully understand Optune Pax adoption and payer behavior, especially in the U.S. Private payer coverage could take one to two years to mature and updates to Medicare coverage can take up to around two years, creating medium‑term visibility challenges.

LUNAR‑2 Strategy Under Review

The company is actively reassessing its LUNAR‑2 lung cancer trial strategy to compress timelines and reduce cost, with plans to consult regulators on potential adjustments. While this could ultimately streamline development for Optune Lua in lung cancer, it injects uncertainty into the approval path and timing.

Early Launch Conversion Constraints

NovoCure acknowledged that early Optune Pax conversion metrics reflect normal launch friction, with 169 prescriptions leading to 90 patient starts and 83 on therapy by quarter‑end. Management framed this as a function of limited time between approval and the reporting date, but investors will track conversion rates closely in coming quarters.

Higher R&D and Sales Spend Weigh on the Bottom Line

Operating expenses continued to rise as the company funds its growth agenda, with R&D up 8% to $58 million on the back of KEYNOTE D58 and other trials. Sales and marketing spending also rose 5% to $58 million, reflecting launch investments for Optune Pax and Optune Lua that keep near‑term pressure on earnings.

Guidance and Management Outlook

Management’s updated 2026 guidance calls for net revenue of $690 million–$710 million, with the midpoint at $700 million and combined Optune Pax/Lua revenue of $15 million–$25 million. NovoCure expects full‑year gross margin in the mid‑70s and adjusted EBITDA between negative $15 million and breakeven, supported by a strong Q1 margin of 78% and an adjusted net loss that improves markedly when excluding one‑time items.

NovoCure’s call framed a company at an inflection point, balancing solid revenue growth, a deepening clinical pipeline and improving unit economics against accounting noise and execution risk. For investors, the story now hinges on pacing of Optune Pax adoption, resolution of reimbursement timelines and delivery of upcoming trial readouts that could unlock the next leg of growth.